Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia.

Milo GattiMaddalena GiannellaMatteo RinaldiPaolo GaibaniPierluigi VialeFederico Pea

Published in: Antibiotics (Basel, Switzerland) (2022)

Attaining optimal joint PK/PD targets with a combo-therapy of CI fosfomycin plus EI cefiderocol or CI ceftazidime-avibactam could represent an effective strategy for granting favorable microbiological outcomes in patients with DTR-PA pneumonia and/or BSI.

Keyphrases

gram negative
multidrug resistant
pseudomonas aeruginosa
low dose
acinetobacter baumannii
drug resistant
cystic fibrosis
healthcare
klebsiella pneumoniae
respiratory failure
stem cells
metabolic syndrome
type diabetes
mesenchymal stem cells
intensive care unit
electronic health record
glycemic control
cell therapy